Perioperative challenges in management of diabetic patients undergoing non-cardiac surgery

Abstract

Prediabetes and diabetes are important disease processes which have several perioperative implications. About one third of the United States population is considered to have prediabetes. The prevalence in surgical patients is even higher. This is due to the associated micro and macrovascular complications of diabetes that result in the need for subsequent surgical procedures. A careful preoperative evaluation of diabetic patients and patients at risk for prediabetes is essential to reduce perioperative mortality and morbidity. This preoperative evaluation involves an optimization of preoperative comorbidities. It also includes optimization of antidiabetic medication regimens, as the avoidance of unintentional hypoglycemic and hyperglycemic episodes during the perioperative period is crucial. The focus of the perioperative management is to ensure euglycemia and thus improve postoperative outcomes. Therefore, prolonged preoperative fasting should be avoided and close monitoring of blood glucose should be initiated and continued throughout surgery. This can be accomplished with either analysis in blood gas samples, venous phlebotomy or point-of-care testing. Although capillary and arterial whole blood glucose do not meet standard guidelines for glucose testing, they can still be used to guide insulin dosing in the operating room. Intraoperative glycemic control goals may vary slightly in different protocols but overall the guidelines suggest a glucose range in the operating room should be between 140 mg/dL to 180 mg/dL. When hyperglycemia is detected in the operating room, blood glucose management may be initiated with subcutaneous rapid-acting insulin, with intravenous infusion or boluses of regular insulin. Fluid and electrolyte management are other perioperative challenges. Notably diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic state are the two most serious acute metabolic complications of diabetes that must be recognized early and treated.

Core Tip: Diabetes is a common endocrine condition with multiple organ system involvement. Careful preoperative assessment and perioperative management is crucial in preventing perioperative morbidity and mortality in patients with diabetes presenting for surgery. The focus of preoperative risk assessment should be to assess and optimize the level of glycemic control, as well as identification of possible systemic comorbidities. Intraoperatively the focus is to ensure euglycemia, prevent metabolic and electrolyte derangements and maintain adequate organ perfusion. Postoperatively patients should be transitioned back to their home regimen once adequate oral intake is established.

INTRODUCTION

The prevalence of diabetes in the United States is about 10%. Additionally about one third of the United States population is considered to have prediabetes. The prevalence amongst surgical patients is most likely even higher, as prediabetic and diabetic patients are more likely to require surgical procedures due to the associated micro and macrovascular complications of diabetes. Surgical procedures are associated with an up-regulation of catecholamines, cortisol, and inflammatory cytokines, which subsequently decrease insulin sensitivity and increase secretion of glucagon and growth hormone[1]. These hormonal changes are enhanced in patients with insulin resistance. This leads to a catabolic state with increased gluconeogenesis, glycogenolysis, lipolysis, proteolysis and ketogenesis. This ultimately can result in hyperglycemia and potentially even to ketoacidosis[1]. Consequently, diabetic patients are at higher risk for postoperative morbidity and mortality after non-cardiac surgery, both short-term (21 d after surgery) and long-term (7 years), due to associated cardiac, renal, neurologic, metabolic, and endocrine complications[2,3]. Careful preoperative evaluation, optimization of preoperative comorbidities, and meticulous management of patients with diabetes during the perioperative period is essential to reduce perioperative mortality and morbidity. In this article we will discuss important aspects of preoperative evaluation and optimization, as well as the perioperative prevention and management of complications in diabetic patients presenting for non-cardiac surgery[4-9] (Figure 1).

Figure 1.

Preoperative management algorithm for diabetic patients undergoing non cardiac surgery. HbA1c: Hemoglobin A1C; BG: Blood glucose; EMR: Electronic medical record; EKG: Electrocardiogram; HR & Pulse Ox: Heart rate & Pulse Ox.

PRE-OPERATIVE ASSESSMENT AND MANAGEMENT

Diabetes is a common chronic endocrine condition which has an ever increasing prevalence. About half of diabetic patients are undiagnosed[10]. Diabetes is often first diagnosed during the preoperative workup in patients presenting for surgery[11,12]. A recent systematic review summarized, that there is currently insufficient evidence to support routine screening of blood glucose and/or hemoglobin A_1C (HbA_1c) in otherwise healthy patients undergoing elective surgery[13]. The American Diabetes Association recommends screening for diabetes in all overweight patients who have an additional risk factor. Risk factors include a history of cardiovascular disease, hypertension, hyperlipidemia, polycystic ovarian syndrome, or gestational diabetes, a first-degree relative with diabetes, or a higher risk race or ethnicity[14,15]. These guidelines are not specific for patients having surgery, however it makes intuitive sense to screen these patients, who are at risk for diabetes, before surgery.

Management of diabetic patients should involve a multidisciplinary approach. The main goals include a thorough pre-operative risk assessment and optimization, meticulous blood glucose control in the perioperative period and prevention and management of perioperative diabetic emergencies.

Preoperative assessment includes a thorough history and physical examination. History should include the type and duration of diabetes, degree of blood glucose control, current medications, presence of end organ damage and hospitalizations due to diabetic complications[12,16]. Glycated HbA_1c and the blood glucose should be measured. The average home blood glucose levels should be assessed from history or review of charts[17]. Review of these lab measurements will indicate the degree of blood glucose control which will indicate the potential of hyper or hypo glycemic episodes in the perioperative period. Although HbA_1c level exceeding 8% is associated with higher risk of postoperative complications, there is insufficient evidence to determine the upper threshold HbA_1c level in which surgical cancellation or delay should be considered[3,18-21]. That being said, the etiology of the increased incidence of adverse perioperative events in diabetic patients may be related to presence of macro and microvascular complications due to long standing diabetes[3,21-26]. Consequently, the patient’s diabetic control should be optimized before surgery with a target HbA_1c less than 8% and a regimen targeted towards consistent normoglycemia. If the HbA_1c is more than 8% consideration should be given to postponement of elective surgery regardless of lack of established guidelines. Perioperative glucose levels (perioperative defined as day of surgery until third postoperative day) correlate more with surgical complications than the preoperative HbA_1c-level[27]. Unsurprisingly, a high HbA_1c is often associated with high perioperative blood glucose levels. Increased preoperative blood glucose levels are associated with increased risk of surgical complications after spinal, vascular, colorectal, trauma, breast, orthopedic and hepatobiliary[28,29] surgery[17,24]. Preoperative elevation of blood glucose exceeding 300 mL/dL, hyperosmolar hyperglycemic state, and diabetic ketoacidosis are further suggested indication for postponement of elective surgery.

Antidiabetic medication regimens need to be carefully reviewed and adjusted during the pre-surgical assessment to avoid unintentional hypoglycemic and hyperglycemic episodes. Adjustment and withholding of medications are crucial, as patient are fasting for several hours before surgery and therefore are at high risk of experiencing hypoglycemia. Generally, antidiabetic medications including metformin, glucagon-like peptide-1 agonists, sulfonylureas, and thiazolidinediones should be held on the day of surgery (Table 1)[30]. Sodium-glucose cotransporter (SGLT 2) inhibitors should be held for at least 3 d before surgery (Table 1).

Table 1.

Preoperative medication-management in diabetic patients (dosages may need to be individualized to the patient)

Drugs	Day before surgery	Day of surgery
Metformin, Sulfonylurea (oral hypoglycemics)	Daily same dose	Hold on the day of surgery
Canaglifozin, Dapagliflozin, Empagliflozin (SGLT2 inhibitors)	Stop 3 d before surgery	Hold on the day of surgery
Ertuglozin (SGLT2 inhibitor)	Stop 4 d before surgery	Hold on the day of surgery
Injectable non-insulins	Normal dose the night before surgery	Hold on the day of surgery
Insulin pump	Depending on the insulin pump protocol	Depending on the insulin pump protocol
Levemir, Lantus, NPH (long-acting basal insulin)	Normal dose the night before surgery	Half the normal dose in the morning of surgery
Combination of long and short acting (mixed insulin)	Normal dose the night before surgery	Depending to the fasting blood glucose: If > 200 mg/dL: Take half of the normal dose; If < 200 mg/dL: No insulin

SGLT2: Sodium-glucose cotransporter 2. NPH: Neutral protamine hagedorn.

In general, elective surgical procedures do not need to be cancelled or postponed, if the patient accidentally took an oral antidiabetic medication on the day of surgery. Cancellation of postponement of elective surgery should be considered if the patient accidentally took any SGLT 2 inhibitor or a sulfonylurea because of the risk of hypoglycemia or diabetic ketoacidosis[15].

Insulin dependent patients require careful preoperative evaluation and education on an individual basis. Home insulin regimens and fasting glucose measurements need to be reviewed. Patients with type 1 diabetes require insulin due to its absolute deficiency, while only a fraction of patients with type 2 diabetes need insulin. type 2 diabetic patients are also usually on higher individual doses of insulin, compared to type 1 diabetic patients. Insulin medications are classified according to their time to onset, time to peak, and duration of action. Insulin formulations may be rapid-acting, short-acting, intermediate-acting, or long-acting/basal insulins. Premixed insulins are also available.

Regimens for patients with type 1 diabetes typically cover the basal requirement, prandial and correctional insulin for anticipated nutritional intake or unanticipated accidental hyperglycemia[31]. Preoperatively, long-acting insulins are less likely to result in hypoglycemia and should therefore not be withheld. Half the normal dose of intermediate insulin should be taken on the day of surgery. Rapid-acting insulin should be withheld in patients with a blood glucose below 200 md/dL and carefully titrated in patients with blood glucose exceeding 200 ng/dL. General guidelines for insulin are summarized in Table 2. It may be reasonable to reduce the doses of insulin in patients with type 2 diabetes, although there is currently limited consensus. A reduction of basal insulin by 20%-25% the night before surgery was reported to be sufficient to achieve adequate blood glucose levels on the day of surgery[32]. Long-acting insulin should be reduced by 50% on the morning of surgery. Intermediate-acting insulin should be maintained the day before surgery, but a 25% or 50% reduction in doses is recommended the night before and the day of surgery. Short-acting insulin should generally be avoided on the day of surgery and only be administered according to actual blood glucose levels. It is useful to consult an endocrinologist for patients who have a subcutaneous insulin pump. Recommendations regarding potential changes in insulin regime may be required preoperatively. It is recommended that insulin pumps should be disconnected in emergency cases and surgeries lasting more than 3 h. A continuous infusion of insulin and titration according to actual blood glucose level is recommended[31,33].

Table 2.

Insulin treatment on the day of surgery

Insulin types	Regiment on the day of surgery
Lantus/Toujeo, Tresiba, Levemir (long-acting insulins)	Half dose of normal in the morning of surgery
NPH-insulin (intermediate insulin)	Half dose of normal in the morning of surgery
Inulin aspart protamine, insulin aspart; Insulin lispro protamine, insulin lispro; Insulin neutral protamine hagedorn and insulin regular (all mixed insulin)	Depending to the blood glucose: If > 200 mg/dL: Take half of the normal dose in the morning; If < 200 mg/dL: No insulin
All models of insulin pumps: Endocrinology consult recommended, except patient ambulatory	Basal rate until operation, continue with iv insulin during surgery

Specific assessment of the different organ systems

Cardiovascular: Cardiovascular death is a major source of morbidity and mortality in the diabetic patient. Up to 50% of the type 2 diabetic patients have unrecognized myocardial infarction events[17,34]. As well as coronary artery disease, patients with diabetes have a prevalence of heart failure due to diabetic cardiomyopathy that range from 19%-26%. This prevalence is higher than in age-matched individuals without diabetes[35,36]. These changes occur due to cardiac fibrosis with cell signaling abnormalities that lead to a stiff heart. This results in diastolic dysfunction and heart failure with preserved ejection fraction or sometimes heart failure with reduced ejection fraction[37]. Diabetic cardiomyopathy may be present without the existence of other cardiac risk factors.

Another major cardiovascular concern is cardiac autonomic neuropathy (CAN). This serious complication of diabetes mellitus is associated with a 5-fold increased risk of cardiovascular mortality[38,39] and cardiovascular events[40,41]. Patients with CAN often suffer from exercise intolerance, postural hypotension, dizziness and syncope[38,39]. A patient with CAN may present with sinus tachycardia, abnormal blood pressure regulation, intraoperative cardiovascular and hemodynamic instability and asymptomatic myocardial ischemia and infarction. Current recommendation suggests that CAN be evaluated preoperatively in patient with Type 1 diabetes. Tests such as Valsalva maneuver [heart rate (HR) change], electrocardiogram (ECG), long-term-ECG (HR variability), QT measurement, ambulatory BP-monitoring (dipping) may be performed[17]. These tests may confirm an imbalance in autonomic regulation. If autonomic dysregulation is found to exist, it may be prudent to avoid medications that could induce orthostatic hypotension. The ventilatory response to hypoxemia, hypercapnia and the patient’s response to hypothermia may also be affected[42,43].

Diabetes is a risk factor for myocardial injury after non-cardiac surgery[34]. Elective troponin screening on the day of surgery and the first three days after surgery should therefore be considered[34,44]. Cardiology should be consulted if troponin level is elevated, with or without clinical symptoms suggestive of an acute cardiac event[34]. Diabetes also increases the risk of peripheral artery and cerebrovascular disease. However, there are no specific considerations regarding perioperative anesthesia management of these disease states in the diabetic patient.

Airway and respiratory tract: Diabetic and obese patients are anecdotally considered to be at high risk for difficult intubation[45]. A large retrospective analysis of surgical patients indicate, that increasing BMI was associated with increasing odds of difficult intubation[46]. Obese patients are harder to intubate than lean patients, but difficult intubation is no more likely in morbidly obese patients than in those who are only slightly obese[46]. Well-known signs and tests such as the Mallampati-test, Wilson’s scale, “prayer sign”, and palm-print, help predict the possibility of a difficult airway. Stiff joints occur in diabetics due to glycosylation of tissue proteins. The abnormal collagen accumulates in the joints, including the atlanto-axial and temporomandibular joints. This leads to an impaired mobility of the neck and mouth which can result in difficult intubation[47,48].

Diabetic patients are also susceptible to postoperative respiratory infections. This is further exacerbated by obesity and history of smoking if these risk factors coexist. In these situations, adequate perioperative pulmonary testing and treatment should be initiated.

Renal: Diabetes is one of the most common causes of kidney disease and subsequently end-stage renal failure. Therefore, renal function should be assessed with serum creatinine concentration and GFR (glomerular filtration rate) in all patients having moderate-to major non-cardiac surgery[17].

Gastrointestinal: Gastroparesis is a major consideration for anesthesiologists. Gastroparesis is defined by a delayed emptying of the stomach, although there is often no anatomical outlet obstruction[49]. Gastroparesis can result in regurgitation and pulmonary aspiration of gastric content during the intubation process. Therefore, identification of patients at risk for gastroparesis is essential during the preoperative risk assessment. It may be prudent to perform a rapid sequence intubation and to premedicate with famotidine, metoclopramide and sodium citrate in diabetic patients with suspected gastroparesis.

Peripheral neuropathy: More than half of diabetic patients develop some type of peripheral neuropathy during their lifetime. It occurs due to a damage of peripheral nerves. Presentation is variable depending on which nerves are affected. It can affect the motor nerves (control of the movements), the sensory nerves (touch, temperature, pain) or the autonomic nerves (digestion, heartrate, breathing). Most diabetics with peripheral neuropathy suffer from polyneuropathy. An existing peripheral neuropathy must be adequately documented, especially if regional anesthesia, extreme positioning or placement of an arterial line is considered.

INTRAOPERATIVE MANAGEMENT OF DIABETES MELLITUS

Management of a potentially difficult airway, and prevention of renal failure and electrolyte disturbances are some of the important considerations when anesthetizing a diabetic patient. Meticulous monitoring of fluid and electrolyte balance is warranted as glucose has osmolar effects which can lead to serum electrolyte imbalance. Optimal blood glucose levels ranging between 120-180 mg/dL should be maintained. Simultaneously, hypoglycemic and hyperglycemic episodes should be strictly avoided.

Intraoperative glucose monitoring

Close monitoring of blood glucose during surgery is mandatory, as symptomatic hypoglycemia (tremor, anxiety, palpitations, or sweating) is masked by general anesthesia. Iatrogenic or accidental (over)administration of antidiabetic medications including preoperative oral medications and insulins are potential causes of intraoperative hypoglycemia. Other causes of intraoperative hypoglycemia include, inappropriate blood glucose monitoring, drug errors, and interruption of enteral or parental nutrition[50].

Hyperglycemia during surgery in a diabetic or non-diabetic patient might be mediated by the following: (1) Stress associated with the procedure, which alters the balance between hepatic glucose production and use[50]; (2) Inflammation which may interfere with peripheral glucose uptake promoting a state of relative insulin resistance[50]; (3) Use of dexamethasone for prevention of postoperative nausea and vomiting[50,51]; and (4) Volatile anesthetics leading to decreased insulin secretion[51].

Hyperglycemia is associated with poor outcomes such as postoperative infections, acute renal failure, acute myocardial infarction, increase 30-d mortality and longer intensive care unit (ICU) and hospital stays[52]. It has been reported that nearly 12%-30% of patients without previous history of diabetes may have hyperglycemia during surgery[3,51].

There are several options for measuring blood glucose intraoperatively. The most common in the operating room is the capillary blood. However, it is limited by a time constant for venous blood turnover which affects accuracy compared to a venous sample[51]. Peripheral intravenous catheter, arterial lines and central venous catheters are other alternatives for sampling. Central laboratory device is the gold standard glucose measurement. The limitation with central laboratory device is a turn-around-time of over an hour and the large sample volume needed, in comparison with blood gas analysis and point-of-care testing. Both have shorter turn-around-time and need smaller sample sizes. However, they but are less accurate, especially point-of-care testing[51]. Nevertheless, blood gas analysis, venous phlebotomy and point-of-care testing are the most frequently used devices to measure glucose in the perioperative setting despite their various limitations[50].

Neither arterial nor capillary whole blood glucose meet standard guidelines for blood glucose testing in acute and chronic care facilities. This suggests that caution must be exercised when using glucose meter values to dose intravenous insulin or when using more intensive glycemic control protocols[53]. Although point-of-care and arterial blood gas testing can be used to monitor glucose in the operating room, even for patients on an intravenous insulin infusion, we should be aware of the inaccuracy of these methods and the potential for significant harm[54].

Continuous glucose monitors (CGM) are not currently approved in perioperative setting[51] and have not been thoroughly evaluated in the intraoperative period[55]. In the future CGM might be a potential tool to monitor glucose level during surgery. CGM are usually minimally invasive and measure glucose in the interstitial fluid every 1 min to 5 min[50,55]. However, there is insufficient data on their accuracy during surgery. Common events during the course of surgery such as hypotension, hypothermia, hypoxia and electrical interference may also significantly affect their reliability[55]. Consensus statements[56] for inpatient use of CGM, including ICU, do exist, however these do not address monitoring issues in the operating room.

On the horizon, there are potential tools that might be useful for intraoperative glucose monitoring. One of these technologies involves a non-invasive monitoring of blood glucose using optical methods[57]. These devices have not been tested in the intraoperative setting, and many of them are prototypes. However, they could help to surmount the inconvenient frequent blood sampling of the point-of-care testing and the invasiveness of some CGM. Potential sampling sites include the skin (finger, lip, arm, hand, and ear lobe) or easily accessible body fluids (tear fluid, sweat, and saliva). With this technology the arterial vasculature can be accessed as with pulse oximetry. However, variations in signal amplitude and phase must be overcome to reach stable signals with an appropriate signal-to-noise ratio[57].

Intraoperative glucose management

As a general principle, prolonged preoperative fasting should be avoided and diabetic patients should have a surgical time scheduled for as early as possible in the morning.

The goals or target towards avoidance of hyperglycemia and hypoglycemia may change between different societal guidelines and institutional protocols. Intraoperative glycemic control goals are quite similar between most major guidelines[30]. Overall, the guidelines suggest a glucose target in the range of 140 mg/dL to 180 mg/dL intraoperatively[50]. The Association of Anesthetists of Great Britain and Ireland suggests a goal between 110 mg/dL and 180 mg/dL (6-10 mmol/L), with an upper limit of 216 mg/dL (12 mmol/L) in patients with previous poor control[21]. In general, the guidelines encourage initiation of insulin when glucose levels are greater than 180 mg/dL, and administration of intravenous glucose of levels below 70 mg/dL[21,30]. Tighter and more aggressive glycemic control have failed to show significant impact on clinical outcomes and are associated with a high risk of hypoglycemia[58]. Baseline blood glucose level should be assessed before surgery, preferably as close as possible to induction of general anesthesia. Thereafter, blood glucose level should be assessed regularly, and should not exceed 2 h between measurements[59].

When hyperglycemia is detected in the operating room, blood glucose management may be initiated with subcutaneous rapid-acting insulin, with intravenous insulin infusions or boluses of regular insulin[1,30,50]. The type of insulin and route of administration depends on different factors. Good candidates for subcutaneous insulin are patients undergoing ambulatory surgery or procedures of short duration (less than 4 h)[30]. Usually, an intravenous insulin infusion is recommended for patients undergoing procedures with anticipated hemodynamic changes, significant fluid shifts, expected changes in temperature, use of inotropes, or lengthy operative times (greater than 4 h)[30,60]. Some guidelines suggest that intravenous insulin infusions are overused in the perioperative setting and are associated with hypoglycemia, hyperglycemia, ketosis, and hyponatremia[21]. An insulin infusion may be considered in patients who will miss more than one meal and in type 1 diabetics who have not received background insulin or have poorly controlled diabetes (HbA_1c > 69 mmol/mol or 8.5%)[21].

The dose of subcutaneous rapid-acting insulin can be calculated depending on the glucose measurement and the presence of insulin resistance. Correctional insulin dosing is intended to treat glucose measures greater than 180 mg/dL and can be calculated by measuring glucose minus 100/insulin sensitivity factor[30,61]. Insulin sensitivity factor is equal to 1800 divided by the patient’s total daily dose of insulin or 40 if the patient was previously taking oral medications[30].

With regard to intravenous insulin infusion, institutions should have a protocol that allows flexible rate adjustment based on current and previous glucose values[30]. Patients with type 1 diabetes generally begin the insulin infusion rates at 0.5-1 U/h, whereas infusion rates for type 2 diabetics generally begin at approximately 2-3 U/h or higher due to presence of insulin resistance[1].

Corticosteroids, specifically dexamethasone are often administered for the prevention of postoperative nausea and vomiting. They are also used to reduce postoperative stridor and airway edema. Current evidence suggests administration of low dose dexamethasone in these situations (4-5 mg) with close monitoring of glucose in diabetics after administration (hourly for at least 4 h)[21,50].

Insulin pump management

There is limited evidence on the use of a patient’s home insulin pump during surgery. There is also a wide variation in practice regarding continuing a patient’s home insulin pump intraoperatively. Some advocate continuing the pump during the procedure, others advocate discontinuing the pump and using an intravenous insulin infusion or using injectable subcutaneous insulin alone[50]. Recommendations rely on different factors such as the type of surgery, the ability of the provider to safely manage the pump, the fasting period, and the period of time until the patient can control the pump following surgery[50]. The Society for Ambulatory Anesthesia suggest that if the pump is not in the surgical field, and the patient and surgery meet the criteria for subcutaneous insulin use, a patient’s home pump can be continued in the operating room[59] using the preprogramed basal rate[30]. If use of the home insulin pump is not feasible, intravenousinsulin infusion can be substituted for the pump. In this situation, the pump is disconnected, and an insulin infusion started at the same basal rate used by the patient[30].

Fluid and electrolyte management

The aim of perioperative fluid therapy is to avoid dehydration and to maintain electrolyte balance. The recommendation in general is to avoid solutions with glucose, unless required for avoidance of hypoglycemia due to prolonged fasting[61]. Although 0.9% normal saline was traditionally the fluid of choice for patients with diabetes, balanced salt solutions are increasingly recommended in order to prevent hyperchloremic metabolic acidosis which can be associated with normal saline administration[61]. To avoid insulin-induced hypokalemia, potassium should be evaluated at least every 4 h during surgery[62].

POST-OPERATIVE MANAGEMENT

Postoperative hyperglycemia is associated with a higher risk of infections and prolonged hospital stay[63]. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic state are the two most serious acute metabolic complications of diabetes. In recent years, reports of hyperosmolar, hyperglycemic, nonketotic diabetic coma have proliferated greatly. The interaction of several commonly employed medications with hyperglycemic potential in the management of the critically ill surgical patient has been a major cause of hyperosmolar coma[64].

Transition to euglycemic state

Intravenous insulin is the preferred medication to maintain normoglycemia in patients in the operating room and ICU. The short half-life of intravenous insulin (35 min) allows easy titration and discontinuation in the event of unpredicted changes in patient’s health, concurrent medications, and nutrition. An insulin infusion should be initiated in the operating room or ICU when a patient’s blood glucose is ≥ 180 mg/dL. A variety of insulin protocols have been shown to be effective in achieving glycemic control, while minimizing hypoglycemic events and improving hospital outcomes[65]. The insulin infusion is transitioned to sliding scale insulin postoperatively. Blood glucose levels should be measured regularly, preferably every 6-8 h. Serum electrolytes should be measured daily. Sliding scale insulin should be transitioned to the regular home medications or a regimen familiar to the patient once the patient resumes their regular oral intake. During transition, patients should have more frequent routine glucose measurement during hospitalization. However, individual strategies depend on patient’s conditions, oral intake, and compliance.

CONCLUSION

Diabetes is a common endocrine condition which involves multiple organ systems. Careful preoperative assessment and perioperative management is crucial to the prevention of perioperative morbidity and mortality in patients with diabetes presenting for surgery. The focus of preoperative risk assessment should be to evaluate and optimize the level of glycemic control, as well to identify possible systemic comorbidities. Intraoperatively, the goal is to ensure euglycemia, prevent metabolic and electrolyte derangements and maintain adequate organ perfusion. Postoperatively patients should be transitioned back to their home regimen once adequate oral intake is established.